SBC Medical Group Holdings Incorporated (SBC) is a Nasdaq-listed medical services organization that provides management, marketing, staffing, procurement and IT support to a network of roughly 293 aesthetic, dermatology, dental, orthopedic, fertility and hair-loss clinics, primarily in Japan under the Shonan Beauty Clinic brand, with expanding operations in the United States and Southeast Asia. The stock traded at $5.52 on Thursday morning, a decline of 11.96% from the previous session's close of $6.27, after gapping lower at the open and touching an intraday low near $5.34. The direction was clearly negative, and the immediate cause cited by the market was the company's disclosure of two cybersecurity incidents affecting customer information in Japan.
Late Wednesday, after the U.S. close, SBC said its security monitoring detected anomalous activity on November 16, prompting it to isolate an affected server, block unauthorized access, preserve logs and commission an outside forensic investigation. The company confirmed that an unauthorized third party accessed and extracted customer information, though it said it has not confirmed acquisition of electronic medical records, clinical treatment histories or reservation-site data, and that the operator of the Tribeau platform invalidated all managed-clinic accounts there.
Critically for investors, management said it cannot yet reasonably estimate the financial or operational impact. It flagged likely costs for customer notification, call centers, forensics, legal and advisory work and potential compensation — partly offset by cyber insurance — and disclosed that affected clinics have suspended television and certain other advertising for a limited period, with new patient inquiries expected to soften during that window. The incident was reported to Japan's Personal Information Protection Commission.
Thursday's slide extends a volatile stretch that began with third-quarter results. Revenue rose 35% to $58.6 million, adjusted EBITDA climbed 66% to $28 million at a 47% margin, and earnings of $0.15 per share beat expectations, sending the stock up 37.6% on November 13 and drawing a price-target increase to $10 from $8. That gain has now been almost entirely surrendered: the shares are back within a few cents of their pre-earnings level of $5.34.
Flows are also exaggerated by structure. Insiders hold more than 80% of shares outstanding and the free float is only about 18 million shares, so relatively modest selling pressure moves the price disproportionately. There were no new analyst rating changes or company announcements beyond the security notice.
Volume was running well above the norm, with roughly 122,000 shares changing hands in the first hour — a pace close to double the 30-day average of about 284,000 shares. Despite the drop, the stock remains above its 50-day moving average near $5.13 and far above its 200-day average, and it is still roughly double its 52-week low of $2.78. The 52-week high of $7.39, set on November 13, now sits about 25% above the current price. Against a market capitalization of roughly $567 million, the reaction was entirely idiosyncratic rather than a sector or macro event.
The score runs from 0, meaning no meaningful news and a move that is ordinary for the stock, to 100, meaning transformative news and an extreme, rare price move. SBC earns 50 out of 100. The verified catalyst is substantive — a confirmed data breach, a regulatory notification, suspended advertising and unquantified remediation costs for a company of modest size — but its financial scope remains undisclosed, which caps how much weight the market can assign it.
The price move was also well outside the norm. At 11.96%, the decline was roughly 3.6 times the stock's average absolute daily move of about 3.3% over the past 60 sessions, a magnitude matched or exceeded only twice in that window. One strong component without the other keeps the score near the midpoint.
Attention now shifts to disclosure detail: whether management quantifies remediation costs or revenue effects, how quickly clinics resume advertising, and whether visit trends hold through the quarter. Fourth-quarter and full-year 2026 results are expected in late March 2027, with consensus looking for roughly $0.12 in EPS on about $51.5 million of revenue. Investors will also track service-fee revisions, Waqoo consolidation benefits, the OrangeTwist build-out in the United States, longevity diagnostics and the AI alliance with NeuroBrain Dynamics.
Risks cut both ways. Governance remains a concern given concentrated insider ownership and limited independent board representation, the $20 million buyback authorization expires December 31 with no shares repurchased as of September 30, and any evidence of lost patient volumes from the breach could pressure estimates.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are surfaced in its curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, letting users compare approaches side by side. For readers tracking volatile names like SBC, reviewing the current leaders is a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The Moving Average Convergence Divergence (MACD) for SBC turned positive on November 13, 2026. Looking at past instances where SBC's MACD turned positive, the stock continued to rise in 35 of 41 cases over the following month. The odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on SBC as a result. In 55 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +40.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where SBC advanced for three days, in 119 of 157 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 99 of 149 cases where SBC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 66%.
The 10-day RSI Indicator for SBC moved out of overbought territory on November 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 19 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 23 of 38 cases where SBC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
SBC broke above its upper Bollinger Band on November 13, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 48 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.965) is normal, around the industry mean (13.131). P/E Ratio (10.500) is within average values for comparable stocks, (49.500). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (2.814). Dividend Yield (0.000) settles around the average of (0.026) among similar stocks. P/S Ratio (2.624) is also within normal values, averaging (26.240).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry DataProcessingServices